A targeted strategy for chronic IBD: discovery of a natural metabolite that accelerates gut mucosal barrier healing 2.5-fold. ✓ Compound generated by commensal bacteria through dietary polyphenol ferm…
🌿 Restoring gut impermeability: The compound curbs endotoxin leakage into the bloodstream by 70% within 24 hours.
🧬 Localized epithelial migration: Eliminates mucosal atrophy commonly caused by prolonged steroid administration.
: 50 nM physiological threshold
: 24 hours in vitro
: Undetectable in preclinical models
: Targeted pH-triggered enteric matrix
A targeted strategy for chronic IBD: discovery of a natural metabolite that accelerates gut mucosal barrier healing 2.5-fold. ✓ Compound generated by commensal bacteria through dietary polyphenol fermentation; ✓ Activates localized growth factors without inducing systemic immunosuppression; ✓ Offers a side-effect-free postbiotic alternative to monoclonal antibodies and steroids.
Ligand engages surface GPR109A receptors, mobilizing enterocyte migration and upregulating occludin/claudin-1 tight junction expression.
Integration complexity remains the primary barrier.
By 2028, oral enteric-coated formulations will enter Phase II trials for Crohn’s disease and ulcerative colitis.